<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088059</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1559-HNCG</org_study_id>
    <secondary_id>2017-000086-74</secondary_id>
    <nct_id>NCT03088059</nct_id>
  </id_info>
  <brief_title>Biomarker-based Study in R/M SCCHN</brief_title>
  <acronym>UPSTREAM</acronym>
  <official_title>A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a biomarker-driven trial that will enroll patients with recurrent or metastatic
      squamous cell carcinoma of the head and neck progressing after first-line platinum-based
      chemotherapy. Based on potential biomarkers and molecular alterations identified in the
      biopsy from the central platform, patients will be allocated in different cohorts. There will
      be biomarker-positive patient cohorts and immunotherapy cohorts.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival Rate (PFSR) at week 16</measure>
    <time_frame>The Progression Free Survival Rate (PFSR) analysis will be performed at week 16 for each patient in cohorts 1, 2 and 3.</time_frame>
    <description>Progression Free Survival Rate (PFSR) at week 16 will be assessed as primary endpoint for all patients from cohorts 1, 2 and 3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response Rate (ORR) at week 16</measure>
    <time_frame>Objective response Rate (ORR) at week 16 will be performed at week 16 for each patient in cohort 4.</time_frame>
    <description>Objective response Rate (ORR) during the first 16 weeks of study treatment will be assessed as primary endpoint for all patients from cohort 4-8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>54 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>48 months after first patient in</time_frame>
    <description>Objective Response Rate will be measured according to both RECIST 1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>54 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>54 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according CTCAE version 4.03</measure>
    <time_frame>54 months after first patient in</time_frame>
    <description>This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, for adverse event reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients included in each patient cohort according the biomarker testing</measure>
    <time_frame>42 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with an evaluable fresh tumor biopsy</measure>
    <time_frame>42 months after first patient in</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Patient Cohort B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are p16 negative and have an EGFR amplification/mutation or PTEN high or HER2 mutation/amplification will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Cohort B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are p16 negative and cetuximab naïve will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Cohort B3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are p16 negative and have an amplification of CCND1 will be randomized between palbociclib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Cohort B4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are p16 negative and 'platinum sensitive' SCCHN will receive niraparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Cohort B5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients whith oropharyngeal cancer and which are p16 positive will receive niraparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Cohort B6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with FGFR1/2/3 mRNA overexpression will receive rogaratinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Cohort I1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are anti-PD(L)1-naïeve or resistant (primary or secondary resistance) will receive IPH2201 antibody (monalizumab).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Cohort I2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient who are PD(L)1 pretreated will be randomized between monalizumab + durvalumab or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Afatinib 40 mg given orally, once daily, 1 cycle is 28 days</description>
    <arm_group_label>Patient Cohort B1</arm_group_label>
    <arm_group_label>Patient Cohort B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)</description>
    <arm_group_label>Patient Cohort B3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care</description>
    <arm_group_label>Patient Cohort B1</arm_group_label>
    <arm_group_label>Patient Cohort B2</arm_group_label>
    <arm_group_label>Patient Cohort B3</arm_group_label>
    <arm_group_label>Patient Cohort I2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPH2201</intervention_name>
    <description>protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days</description>
    <arm_group_label>Patient Cohort I1</arm_group_label>
    <arm_group_label>Patient Cohort I2</arm_group_label>
    <other_name>Monalizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days</description>
    <arm_group_label>Patient Cohort I2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib</intervention_name>
    <description>Niraparib 300 mg given orally, once daily, 1 cycle is 28 days</description>
    <arm_group_label>Patient Cohort B4</arm_group_label>
    <arm_group_label>Patient Cohort B5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1163877</intervention_name>
    <description>Rogaratinib 600 mg given orally, twice daily, 1 cycle is 28 days</description>
    <arm_group_label>Patient Cohort B6</arm_group_label>
    <other_name>Rogaratinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          -  Histologically confirmed recurrent and/or metastatic SCCHN of the oral cavity,
             oropharynx, hypopharynx or larynx not amenable to curative treatment.

          -  At least one measurable lesion by MRI or CT-scan according to RECIST 1.1, evaluated
             within 2 weeks prior to registration. Such lesion must not have been previously
             irradiated; if the measurable lesion(s) have been irradiated, clear progression must
             be documented.

          -  Progressive disease after first line platinum-based chemotherapy with or without
             cetuximab given as palliative treatment or progressive disease within 1 year if
             platinum-based chemotherapy was given as a part of the multimodal curative treatment.
             Patients pre-treated with anti-PD1/anti-PDL1 are allowed.

          -  ECOG performance status 0 -1 with a life expectancy of at least 12 weeks.

          -  Tumor core biopsy from any accessible tumor at the recurrent or metastatic site
             available for central testing.

          -  Patients must have adequate organ function, evaluated within 14 days prior to cohort
             allocation:

          -  Hemoglobin ≥ 9 g/100 ml,

          -  Neutrophils ≥ 1,500/mm3,

          -  Platelets ≥ 100,000/mm3,

          -  Total bilirubin &lt;1.5 times the upper limit of normal (ULN) (&lt; 3 times the upper limit
             of normal for Gilbert's disease),

          -  Serum ALT and AST ≤ 2.5 x ULN,

          -  Adequate renal function measured by:

          -  Estimated creatinine clearance ≥45ml using Cockcroft and Gault formula or Creatinine ≤
             1.5 ULN

          -  International Normalized Ratio (INR) or Prothrombin Time (PT) must be within the
             normal ranges as per institution's standard. A window of 5% is allowed.

          -  Patients receiving anticoagulant therapy are allowed to participate as long as the
             PT/INR values are within the expected target range of their current dose.

          -  Clinically normal cardiac function based on -left ventricular ejection fraction (≥
             50%) as assessed either by multi-gated acquisition scan or cardiac ultrasound and 12
             lead ECG without clinically relevant abnormalities.

          -  Patients ≥ 18 years old and must be able to give written informed consent.

          -  Patients ≥ 70 years old must undergo the G8 screening.

          -  Women of child-bearing potential must have a negative pregnancy test (serum or urine
             within the 72 hours prior to cohort allocation).

          -  Patients of childbearing / reproductive potential must agree to use highly effective
             methods of contraception based on the Clinical Trial Facilitation Group (CTFG)
             guidance as of registration and up to 6 months after the last treatment dose. Highly
             effective methods can achieve failure rate of less than 1% per year when used
             consistently and correctly. Such methods include: For Women: combined (estrogen and
             progestogen containing) hormonal contraception associated with inhibition of ovulation
             (oral, intravaginal and transdermal), progestogen-only hormonal contraception
             associated with inhibition of ovulation (oral, injectable, implantable), intrauterine
             device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized
             partner and sexual abstinence. For Men: condoms, sexual abstinence (the reliability of
             sexual abstinence needs to be evaluated in relation to the duration of the clinical
             trial and the preferred and usual lifestyle of the patient) and no sperm donations
             during treatment and up to 6 months after last dose of treatment.

          -  Female subjects who are breast feeding should agree to discontinue nursing prior to
             the first dose of study treatment and up to 6 months after the last study treatment.

          -  Before patient registration/randomization, written informed consent must be given
             according to ICH/GCP, and national/local regulations.

        General Exclusion Criteria:

          -  Unresolved and significant toxicity CTCAE version 4.03 grade ≥ 2 from previous
             anticancer therapy other than alopecia.

          -  History of any of the following cardiovascular conditions within 6 months prior to
             registration:

          -  myocardial infarction,

          -  severe/unstable angina,

          -  ongoing cardiac dysrhythmias of CTCAE version 4.03 Grade 2 or more,

          -  atrial fibrillation of any grade,

          -  coronary/peripheral artery bypass graft,

          -  symptomatic congestive heart failure according to New York Heart Association (NYHA)
             Class III or Class IV,

          -  significant active cardiac disease including uncontrolled high blood pressure defined
             as systolic ≥150 and diastolic ≥100.

          -  cerebrovascular accident including transient ischemic attack

          -  thromboembolic events like symptomatic pulmonary embolism.

          -  Nasopharynx and sino-nasal tumor.

          -  Surgery or investigational drugs or chemotherapy or other anticancer therapy within 3
             weeks before cohort allocationor or for investigational drugs, within a time interval
             less than at least 5 half-lives of the investigational agent, whichever is shorter.
             Participant must have recovered from any surgical procedure. Curative radiation
             therapy (60-70 Gy) within 6 weeks of cohort allocation. Palliative radiation therapy
             (e.g. 8 Gy on a painful lesion) will be allowed.

          -  Known untreated and uncontrolled brain metastases or leptomeningeal carcinomatosis.

          -  Known diagnosis of immune deficiency or a positive serology of Human Immunodeficiency
             Virus (HIV) (HIV 1/2 antibodies).

          -  Active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative]
             is detected) or pre-existing liver cirrhosis.

          -  Known pre-existing interstitial lung disease (ILD). Bronchoemphysema is not considered
             as ILD.

          -  Other uncontrolled active illnesses or nonmalignant systemic disease (examples
             include, but are not limited to active infections requiring antibiotics, bleeding
             disorders, uncontrolled diabetes, uncontrolled ventricular arrhythmia, uncontrolled
             major seizure disorder, unstable spinal cord compression, superior vena cava syndrome
             …).

          -  Any psychiatric, psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule.

          -  Any malignancy (other than SCCHN, non-melanoma skin cancer or localized cervical
             cancer or localized and presumed cured prostatic cancer or basal cell carcinoma of the
             skin and carcinoma in situ of the cervix or bladder) within the last 3 years prior to
             treatment allocation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>EORTC HQ</last_name>
    <phone>+32 2 774 1611</phone>
    <email>1559@eortc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dirk Schrijvers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Pascal Machiels</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yassine Lalami</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi - Grand Hôpital de Charleroi - Site Notre Dame</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Luc Canon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pol Specenier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sylvie Rottey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital De Jolimont</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emmanuel Seront</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Kortrijk - Campus Kennedylaan</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philip Debruyne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paul Clement</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GasthuisZusters Antwerpen - Sint-Augustinus</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Annemie Rutten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dinant Godinne - UCL Namur</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephanie Henry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amaury Daste</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges-Francois-Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sylvie Zanetta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cyril Abdeddaim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frederic Rolland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Esma Saada-Bouzid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe Le Tourneau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marie-Christine Kaminsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Caroline Even</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cecilia Moro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lorenzo Livi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lisa Licitra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Paolo</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Darris Ferrari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS &quot;Fondazione G. Pascale&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francesco Caponigro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust (UHB) - UHB-Queen Elisabeth Medical Centre</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anthony Kong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHS Lothian - Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Iain Nixon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Derek Grose</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS - Guy s and St Thomas' NHS - Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Teresa Guerrero Urbano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust - Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sileida Oliveros</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernadette Foran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>March 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Afatinib</mesh_term>
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

